Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures

Gut

Volumn 57, Issue 9, 2008, Pages 1322-1329

  Veitch, A M ^a   Baglin, T P ^b   Gershlick, A H ^c   Harnden, S M ^a   Tighe, R ^d   Cairns, S ^e  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^d NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^e ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; TIROFIBAN; WARFARIN;

ALGORITHM; ANTICOAGULANT THERAPY; BLEEDING; CONTINUOUS INFUSION; CORONARY STENT; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG WITHDRAWAL; ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT INDICATION; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ALGORITHMS; ANTICOAGULANTS; ENDOSCOPY; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 50249166067     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.142497     Document Type: Review

References (65)

1. Eison GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002;55:775-9.
2. Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc 2005;61:189-94.
3. Goel A, Barnes CJ, Osman H, et al. National survey of anticoagulation policy in endoscopy. Eur J Gastroenterol Hepatol 2007;19:51-6.
4. British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998;101:374-87.
5. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259-69.
6. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. Br J Haematol 2006;132:277-85.
7. Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004;35:2362-7.
8. Seshadri N, Goldhaber SZ, Elkayam U, et al. The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. Am Heart J 2005;150:27-34.
9. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-55.
10. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
11. Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999;19:2007-11.
12. Cappell MS, Abdullah M. Management of gastrointestinal bleeding induced by gastrointestinal endoscopy. Gastroenterol Clin North Am 2000;29:125-67.
13. Wang MQ, Sze DY, Wang ZP, et al. Delayed complications after esophageal stent placement for treatment of malignant esophageal obstructions and esophagorespiratory fistulas. J Vasc Interv Radiol 2001;12:465-74.
14. Neale JC, Goulden JW, Allan SG, et al. Esophageal stents in malignant dysphagia: a two-edged sword? J Palliat Care 2004;20:28-31.
15. Schapiro GD, Edmundowicz SA. Complications of percutaneous endoscopic gastrostomy. Gastrointest Endosc Clin N Am 1996;6:409-22.
16. Ellis WR, Harrison JM, Williams RS. Rupture of spleen at colonoscopy. Br Med J 1979;1:307-8.
17. Janes SE, Cowan IA, Dijkstra B. A life threatening complication after colonoscopy. BMJ 2005;330:889-90.
18. Taylor FC, Frankl HD, Riemer KD. Late presentation of splenic trauma after routine colonoscopy. Am J Gastroenterol 1989;84:442- 3.
19. Tuso P, McElligott J, Marignani P. Splenic rupture at colonoscopy. J Clin Gastroenterol 1987;9:559-62.
20. Bowles CJ, Leicester R, Romaya C, et al. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow? Gut 2004;53:277-83.
21. Gibbs DH, Opelka FG, Beck DE, et al. Postpolypectomy colonic hemorrhage. Dis Colon Rectum 1996;39:806-10.
22. Rosen L, Bub DS, Reed JF III, et al. Hemorrhage following colonoscopic polypectomy. Dis Colon Rectum 1993;36:1126-31.
23. Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient Gl endoscopy: a survey among German gastroenterologists. Gastrointest Endosc 2001;53:620-7.
24. Wexner SD, Garbus JE, Singh JJ. A prospective analysis of 13,580 colonoscopies. Reevaluation of credentialing guidelines. Surg Endosc 2001;15:251-61.
25. Hsieh YH, Lin HJ, Tseng GY, et al. Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative study. Hepatogastroenterology 2001;48:1379-82.
26. Oda I, Saito D, Tada M, et al. A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer 2006;9:262-70.
27. Vaira D, D'Anna L, Ainley C, et al. Endoscopic sphincterotomy in 1000 consecutive patients. Lancet 1989;2:431-4.
28. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-93.
29. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-18.
30. Nelson DB, Freeman ML. Major hemorrhage from endoscopic sphincterotomy: risk factor analysis. J Clin Gastroenterol 1994;19:283-7.
31. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001;96:417-23.
32. Affi A, Vazquez-Sequeiros E, Norton ID, et al. Acute extraluminal hemorrhage associated with EUS-guided fine needle aspiration: frequency and clinical significance. Gastrointest Endosc 2001;53:221-5.
33. Varadarajulu S, Eloubeidi MA. Frequency and significance of acute intracystic hemorrhage during EUS-FNA of cystic lesions of the pancreas. Gastrointest Endosc 2004;60:631-5.
34. Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004;59:44-8.
35. Friedland S, Soetikno R. Colonoscopy with polypectomy in anticoagulated patients. Gastrointest Endosc 2006;64:98-100.
36. Hittelet A, Deviere J. Management of anticoagulants before and after endoscopy. Can J Gastroenterol 2003;17:329-32.
37. Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep 2004;3:324-30.
38. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005;45:1413-25.
39. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003;163:901-8.
40. Yousfi M, Gostout CJ, Baron TH, et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004;99:1785-9.
41. Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc 1994;40:458-62.
42. Ernst A, Eberhardt R, Wahidi M, et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006;129:734-7.
43. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
44. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
45. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
46. Szekely P. Systemic embolism and anticoagulant prophylaxia in rheumatic heart disease. Br Med J 1964;1:1209-12.
47. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease - native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):457S-82S.
48. Fleming HA, Bailey SM. Mitral valve disease, systemic embolism and anticoagulants. Postgrad Med J 1971;47:599-604.
49. National Institute for Health and Clinical Excellence. Atrial fibrillation. NICE Clinical guideline number 36. London: NICE, 2006.
50. Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 2003;61:964-8.
51. Hull RD, Raskob GE, Brant RF, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000;160:229-36.
52. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992;340:873-6.
53. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(1 Suppl):176S-93S.
54. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2006;114:e84-231.
55. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-41.
56. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA 1978;239:738-9.
57. Katholi RE, Nolan SP, McGuire LB. Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 1976;92:162-7.
58. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
59. Maeng M, Okkels JL, Rasmussen K, et al. Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent. Heart 2007;93:694-7.
60. Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-91.
61. Farb A, Boam AB. Stent thrombosis redux - the FDA perspective. N Engl J Med 2007;356:984-7.
62. lakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
63. Chu MW, Wilson SR, Novick RJ, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004;78:1536-41.
64. Gershlick AH, Richardson G. Drug eluting stents. BMJ 2006;333:1233-4.
65. Shapira Y, Sagie A, Battler A. Low-molecular-weight heparin for the treatment of patients with mechanical heart valves. Clin Cardiol 2002;25:323-7.